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Abstract 
The RNaseA superfamily member Angiogenin (ANG) is a secreted protein involved in 
cell proliferation and stress response. Dysregulation of ANG expression is found in many 
cancers with poor prognosis and mutations in ANG are associated with neurodegenerative 
diseases. While the uptake and nuclear translocation of ANG is relatively well characterised, 
little is known about how it reaches the plasma membrane and its mode of secretion. We 
generated SH-SY5Y neuroblastoma cell lines constitutively expressing wild type (WT) 
Hemagglutinin (HA) epitope tagged mouse Ang1 (mAng1), and two amyotrophic lateral 
sclerosis associated ANG variants (C39W and K40I). Herein, we show that these cell lines 
secrete mAng1 into the culture media. Using small molecule inhibitors we probed the route 
taken between the endoplasmic reticulum and trans-Golgi network during secretion and have 
characterised it as COPII and microtubule dependent. In addition, we show that disruption by 
the PI3-kinase inhibitor wortmannin of the later stages of transit to the plasma membrane leads 
to mAng1 trafficking to lysosomal compartments. This suggests an autophagy dependent 
regulation of secretion.  
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Introduction 
Human ANG is a member of the RNase A superfamily. It is a small single chain polypeptide 
of 123 residues with a relative molecular mass of 14.1kDa [1] and is translated as a pre-protein 
with a signal sequence. Other characteristic features of ANG include the nuclear localisation 
signal, a cell binding motif and the catalytic domain [2,3]. Secreted ANG is taken up and   
translocated to the nucleus in a variety of cell types [3,4]. Althoughthe 3D structure of ANG is 
very similar to RNase A , the active site in ANG is blocked and this leads to the characteristic 
weak ribonucleolytic activity [5].  
ANG is pleiotropic in function and its roles range from vascular remodelling during 
angiogenesis to protection from stress [5, 6]. Besides its role in neovascularization, ANG has 
been shown to be both neurotrophic and neuroprotective [8–11]. Variants in ANG have been 
reported in amyotrophic lateral sclerosis (ALS) [12–15]. ANG mutations are a risk factor for 
ALS in combination with those found in other neurodegeneration associated genes [12]. In 
addition, ANG has recently been shown to play a role in stem cell homeostasis in the 
haematopoietic system [16]. These functions of ANG are mediated intracellularly after 
endocytosis. Under differing cellular contexts ANG has been shown to activate the 
phosphoinositide 3-kinase pathway, cleave transfer RNA (tRNA) in the cytoplasm and 
upregulate ribosomal RNA (rRNA) synthesis by binding to the ANG binding element (ABE) 
of rRNA genes [17].  
ANG is a secreted protein so its export is key to its post-uptake role in target cells/tissue. 
Elevated levels of ANG in the serum have been associated with progression in many types of 
cancers such as colorectal cancer [18,19]. It has also been associated with poor prognosis in 
chronic heart failure [20,21], and has been proposed as a biomarker for both these conditions 
[22]. 
ANG ALS variants can be broadly categorised by their phenotypic effect. While some 
variants alter gross structure (e.g. C39W, P112L) others predominantly affect ribonucleolytic 
activity (e.g. K40I) or the properties of the nuclear/nucleolar localisation signal (e.g. S28N) 
[8]. In addition mutations in the signal sequence such as P(-4)S are also common ALS variants 
but it is unclear how signal sequence mutations affect the function of ANG. As the signal 
peptide is cleaved during secretion from the source tissue, mutations must therefore affect 
secretion after translation and release into the extracellular space. 
We have recently characterised the mechanism of uptake and intracellular trafficking 
to the nucleus [4]. We have shown that impaired intracellular trafficking occurs during uptake 
of gross structural mutants [8]. However, nothing is known about the pathway taken by ANG 
after translation in order to reach the extracellular space, or the  mechanisms regulating 
secretion. We therefore investigated the post-translational trafficking and secretion of ANG 
and its ALS associated variants. ANG is expressed in the nervous system and is present in 
motor-neurons of the spinal cord and dorsal root ganglia [9].Therefore we have used the 
neuroblastoma cell line SH-SY5Y to investigate the secretion of ANG. The trafficking and 
secretion of epitope tagged wild type mAng1 and ALS mAng1variants were perturbed using 
small molecule inhibitors of intracellular transport.  
  
Materials and Methods 
 
Cell lines 
Stable SH-SY5Y cell lines carrying constructs constitutively expressing HA tagged, full length 
wild type mAng1 or the mAng1 ALS-variant K40I and C39W were generated previously by 
transfection of the following constructs -pN1mAngHAWT, pN1mAngHAK40I and 
pN1mAngHAC39W using Fugene6 [18]. The resulting stable cell lines are referred to as SH-
SY5Y WT-, K40I- and C39W mAng1HA respectively [8]. Cell lines were maintained in SH-
SY5Y culture media comprised of DMEM:F12 with Glutamax (Life) and 15%fetal bovine 
serum (FBS) (Labtech), and passaged prior to confluence at least once between revival and 
experimental set-up. Cells were passaged using Trypsin EDTA (Invitrogen) following a 
phosphate buffered saline (PBS) wash. 
 
Treatment with pharmacological agents 
Exponentially growing untransfected and stable SH-SY5Y cell lines expressing wild type 
mAng1HA or the ALS variants were disassociated using Trypsin-EDTA (Lonza) and seeded 
at a density of 105 cells/cm2 onto acid-washed coverslips (SLS) in wells of 24-well plates (BD 
Falcon) in complete medium. Medium was exchanged after 24h with complete medium 
containing the following pharmacological agents at the concentrations indicated: Brefeldin A 
(18mM); Chloroquine (0.1mM); Wortmannin (0.1µM); Lovastatin (1mM); Nocodazole 
(17mM). After treatment with inhibitors for 2.5h, the cells were fixed for 15min in ice-cold 4% 
paraformaldehyde (PFA) (Sigma) in PBS, washed in PBS and then dehydrated to 70% ethanol 
and stored at -200C.  
 
Co-culture 
Untransfected SH-SY5Y cells (5000 cells/cm2) were seeded onto acid-washed coverslips 
(SLS) in wells of 24-well plates (BD Falcon) in complete medium.  Five thousand cells/cm2 of 
WT-, C39W- and K40I-mAng1HA expressing SH-SY5Y clones were seeded onto 33.6mm2 
tissue culture inserts (Greiner, 0.1µm2 pore size, 2x106 cm-2 pore density). After 24h the tissue 
culture inserts were transferred to wells containing the untransfected SH-SY5Y cells on 
coverslips and co-cultured for four days before the cells on coverslips were fixed in PFA as 
above. 
 
Cell Growth Assay 
Exponentially growing untransfected, WT or ALS variant mAng1HA expressing SH-SY5Y 
cells were trypsinised and resuspended in culture medium. After counting by haemocytometer, 
four wells on 24 well plates (BD Falcon) per cell line per time point were seeded in a final 
culture volume of 0.5ml/well of SH-SY5Y complete medium. Four wells per time point of 
media without cells were also plated as controls.  
The Promega 96-well non-radioactive cell titre kit (G4000) was used to assay for cell 
growth, using the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) Four replicate wells of each cell line were assayed at 24h intervals post-plating 
following the manufacturer’s protocols. Cells were incubated with the substrate for 4h at 37°C, 
5% CO2, the reactions were stopped and the insoluble products dissolved by the addition of 
solubilising reagent (G4000 kit) with vigorous rocking for 2h. Contents of each replicate was 
transferred to a flat bottom 96well plate (BD Falcon). Absorbances were read at 570nm with a 
650nm reference wavelength. Three independent experiments were performed and the mean of 
the reference corrected absorbances were plotted against the experiment time course 
 
Differentiation of SH-SY5Y cells on PA6 stromal feeder cells 
Sub-confluent PA6 stromal cells were passaged 1:3 onto gelatin-coated acid-washed coverslips 
on 24 well plates (BD Falcon) in 0.5ml complete PA6 media (alpha MEM supplemented with 
ribonucleosides (Invitrogen), 1% Glutamax (Invitrogen), 10% FBS (Labtech).  Once the PA6 
cells had formed a confluent monolayer, SH-SY5Y cells were seeded onto the monolayer as 
single cells at a density of 5000 cells/well in 0.5ml differentiation media. Differentiation 
medium consists of DMEM:F12 supplemented with 5mM Glutamax (Invitrogen), 1% NEAA 
(Invitrogen), 0.5% Knock-out serum replacement KOSR; Invitrogen) and 10µm all-Trans 
Retinoic Acid (RA; Sigma). Differentiation media was changed every 48h. See [23] for details. 
 
Collection of conditioned media  
Untransfected, WT and ALS variant mAng1HA expressing SH-SY5Y cells were grown to 
confluence in normal medium on 15cm dishes (Becton Dickinson). Media was exchanged for 
serum free DMEM:F12 with additional 5mM L-Glutamine (Invitrogen). The conditioned 
media was collected after four days and passed through 0.22um PES filters (Millipore) and  
concentrated 100x using Amicon Ultra centrifugal filters with a 3kDa cut-off. The concentrates 
were subsequently diafiltered with buffer containing 10mM Tris HCl pH 8.0 and 150mM NaCl. 
Protein concentration was estimated by A280 and 30ug of protein was used for sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS- PAGE) 
 
Western blotting 
Proteins  were resolved on a discontinuous tris-tricine SDS-PAGE (5% stacking gel, 10% 
resolving gel) using Biorad Miniprotean III apparatus. Resolved proteins were blotted onto 
0.22µm PVDF (Pierce) using a Novex semi-dry blotter and buffer containing 48mM Tris 
(Sigma), 39mM glycine (Sigma), 0.037% SDS (Sigma) and 20% Methanol (HPLC grade, 
Fisher).  
Blotted membranes were blocked in 5% Marvel milk powder, 0.1% Tween20 (Sigma) 
in PBS (Oxoid) for one hour at room temperature followed by incubation with mouse anti-
HA.11 (1:5000 , Covance, Clone 16B12) overnight at 4°C in heat-sealed bags. Blots were 
washed (5X5min) in PBS containing 0.1% Tween20 followed by incubation with HRP 
conjugated goat anti-mouse (1:10,000 in block, Abcam, ab6789) secondary antibody for 2h at 
room temperature in heat-sealed bags. Blots were washed (5X5 min) in PBS containing 0.1% 
Tween20. Blots were incubated with electro-chemiluminescent reagents (100mM glycine, 
0.4mM luminal, 8mM 4-iodophenol and 10% dimethyl sulphoxide mixed 1:1 with 0.12% 
hydrogen peroxide) for one minute and exposed to Amersham Hyperfilm MP film (GE 
Healthcare).  
 
Immunocytochemistry 
Fixed cells on coverslips stored in 70% ethanol were rehydrated to PBS and blocked for 1h in 
blocking buffer (1% Gelatin (Sigma), 0.5% Triton (Sigma) and 0.5% FBS (Labtech). Overnight 
incubation at 40C was performed in block containing primary antibodies against the appropriate 
antigen. Cells on coverslips were then washed with 0.1% PBS-TritonX-100 (BDH) and PBS 
alone each 3X5min followed by incubation with fluorophore-conjugated secondary antibodies 
against appropriate primary species for 2h at room temperature. Five further washes with PBS 
were performed then nuclei were counter-stained with DAPI (4′,6-diamidino-2-
phenylindole;Sigma). Two further PBS washes were performed prior to mounting in Mowiol 
with antifade DABCO (1,4-diazabicyclo[2.2.2]octane; BDH) on glass slides (Fisher).  
 
Quantification and statistics 
Images were acquired on a Leica DMRB microscope using Leica DFC490 camera and 
processed using Leica Application Suite (LAS) software. The lengths of neurofilament positive 
neurites were measured in six (660x490µm) randomly selected fields each from three 
independent experiments. Cells positive for cleaved caspase 3 were counted in six 
(660x490µm) randomly selected fields each from three independent experiments. Total cell 
numbers were determined by counting DAPI positive nuclei. Fields of undifferentiated and 
differentiated cells contained 400-500 cells each. Data were compared by ANOVA with 
Dunnet’s post-hoc comparison to untransfected SH-SY5Y cells using Minitab 15. Due to their 
skewed distribution, neurite lengths were Log10 transformed before statistical testing. 
  
Results 
 
Wild type mAng1HA over-expression reduces post-passage recovery period 
There was little observable difference in the growth rate of untransfected SH-SY5Y cells, SH-
SY5Y clones expressing WT-mAng1HA, and C39W- mAng1HA or K40I-mAng1HA ALS 
variants between 24h and 48h after seeding (Fig. 1A). However, between 48h and 72h the 
growth rate of SH-SY5Y WT-mAng1HA cells nearly doubled while the growth rate of 
untransfected SH-SY5Y cells, SH-SY5Y C39W-mAng1HA and K40I-mAng1HA cell lines 
increased only marginally. SH-SY5Y WT-mAng1HA cell growth continued at this higher rate 
until the final time point. After 96h, growth rate of untransfected SH-SY5Y and C39W-
mAng1HA SH-SY5Y increased to a similar level as WT-mAng1HA SH-SY5Y cells. The 
growth rate of SH-SY5Y K40I-mAng1HA cell line appears to remain lower than that of the 
other cell lines between 120h and 144h.  
 
SH-SY5Y cells transfected with mAng1HA process, secrete and endocytose mAng1  
It is unclear whether mAng1 exerts its effects upon proliferation through intra or autocrine 
signalling therefore first we investigated if it was secreted into the culture medium from our 
stable cell lines. In addition to robust uptake and nuclear translocation seen  upon addition of 
purified hANG to the media, we observed a distinct speckled distribution of ANG coverslip 
surface outside the cell body (Fig. 1B). This suggeststhat the  ANG may  be binding to an 
extracellular component. We observed a similar  speckled distribution on the coverslips when 
immunostaining for the HA tagged mAng1 and mAng1 ALS variants. This suggested thatthe 
SH-SY5Y mAng1HA cell lines are secreting ANG into the media. Secretion of the mAng1HA 
variants from the SH-SY5Y cell lines was assessed by Western blot of conditioned media 
collected from each of the cell lines (Fig. 1C). The smallest band picked up by staining with 
the anti-HA antibody consistently runs above the 15kDa marker and was calculated as 17kDa. 
This must represent HA tagged mAng1. The small discrepancy in mass may be due to partial 
refolding or differences in SDS binding in comparison to the marker band, exacerbated by the 
small sizes involved. The 21kDa band is uncharacterised. It is unlikely to be unprocessed ANG 
as it is concentrated from culture medium and therefore must have been secreted by the cells. 
The 24aa signal sequence would only account for an extra 2.48kDa. It is  unlikely to be a 
multimer of mAng1HA as this would be a minimum of 34kDa and the SDS-PAGE used 
denaturing and reducing conditions. Therefore, the 21kDa band most likely represents an 
unknown post-translationally modified species of mAng1HA. Co-culture experiments were 
performed to then determine whether SH-SY5Y cells were capable of taking up the secreted 
Ang. Untransfected SH-SY5Y cells were grown on coverslips in co-culture with WT-, C39W- 
or K40I-mAng1HA expressing SH-SY5Y  grown on transwell filters (Fig. 1D). Untransfected 
SH-SY5Y cells showed uptake of secreted WT-, C39W- and K40I- mAng1HA variants, all are 
seen at low levels in the cytoplasm (Fig. 1E). The two ALS variants were frequently seen to 
accumulate as large aggregates adjacent to the nucleus. WT-mAng1HA signal appears less 
intense than that seen for C39W- or K40I- mAng1HA.Whether this represents reduced uptake, 
faster turnover or is an artefact due to the aggregation of the mutant variants is unclear.  
 
 
Wild type mAng1 over-expression enhances neurite outgrowth of SH-SY5Y cells during 
differentiation 
We have previously shown that exogenously added ALS-associated ANG variant proteins to 
P19 pluripotent cell derived motor-neurons in culture  led to  impaired axon extension and cell 
death [8,10]. We therefore, investigated the effects of over-expression of WT- and ALS-variant 
mAng1HA on SH-SY5Y cells differentiated to a more mature neuronal identity. Length and 
morphology of neurites expressing neurofilament, the mature axonal marker  were assessed 
after differentiation (Fig. 2A, B). SH-SY5Y cells expressing WT mAng1HA possessed longer 
NF positive neurites (median length 79.6 µm, Q1-Q3 45.1-133.8 µm) than untransfected SH-
SH5Y cells (median length 63.5 µm, Q1-Q3 41.9-97.6 µm) or cells expressing either the K40I 
(median length 61.7 µm Q1-Q3 41.4-94.1 µm) or C39W variants (median length 63.6 µm Q1-
Q3 39.7-94.2 µm). No significant differences from untransfected SH-SY5Y neurite length were 
seen in SH-SY5Y expressing either mutant variant.  
 
mAng1 ALS-variants are mis-localised in differentiated SH-SY5Y cells  
TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA-binding protein involved in post-
transcriptional RNA processing. Mutations in TDP43 are also associated with ALS-FTD 
[24,25]. Export of TDP43 from the nucleus to the cytoplasm, and its subsequent cleavage and 
hyper-phosphorylation is associated with stress response and altered stress granule dynamics 
[26]. This is also seen in ALS-FTD pathology where it is found in inclusion bodies [27,28]. 
We have used TDP43 localisation during differentiation to monitor stress in SH-SY5Y cells 
over-expressing WT and ALS-mAng1HA variants. 
The distribution of the  WT-mAng1HA, mAng1HA ALS variants and the ALS 
associated protein TDP43 were analysed upon differentiation of the stably transfected SH-
SY5Y cell lines (Fig. 2C). TDP43 was seen in the nuclei of both PA6 and SH-SY5Y cells. 
Staining with an anti-HA tag antibody showed that the HA tagged WT mAng1 appeared as 
small punctate spots distributed throughout the cytoplasm. No nuclear staining for the HA tag 
was observed. HA tag positive punctae appeared evenly distributed throughout the soma and 
neurites  with an increase in the number of HA+ punctae seen at the distal tip of the neurites. 
The mAng1HA C39W clones showed increased numbers of HA+ punctae in the soma rather 
than the distal tip of neurites. Branching of neurites appears to occur more frequently in shorter 
neurites in C39WmAng1HA expressing cells compared to those in the WT mAng1HA 
expressing clone (Fig. 2A). TDP43 was seen to partially relocate to the cytoplasm in these  cells 
(Fig. 2C, asterisks). In K40I-mAng1HA SH-SY5Y cells, HA+ punctae appear throughout the 
soma and neurite but were found more frequently in the soma in comparison to the WT 
mAng1HA expressing clone. Unlike in the mAng1HA C39W clone, some HA staining was 
seen in the tips of neurites. As in the case C39W mAng1HA clones, TDP43 was observed to 
partially relocate to the cytoplasm in some K40I mAng1HA cells (Fig. 2C, asterisks). 
 
Mutant mAng1HA expression increases apoptosis in differentiated SH-SY5Y cells 
DAPI stained nuclei of SH-SY5Y mAng1HA ALS variant clones upon differentiation showed 
highly condensed or fragmented nuclear material and strongly staining for cleaved caspase 3 
in both nuclei and apoptotic bodies. (Fig. 3A). Increased frequencies of cleaved caspase 3 
positive cells were seen in differentiated cells on day ten when compared to undifferentiated 
populations. After differentiation, significantly more cells positive for cleaved caspase 3 were 
observed in differentiated SH-SY5Y cells expressing C39W mAng1HA in comparison with 
differentiated SH-SY5Y expressing WT- and K40I-mAng1HA or untransfected SH-SY5Y 
(Fig. 3C). In contrast, we found no significant differences in cleaved caspase 3 levels in the 
undifferentiated mAng1HA ALS variant over-expressing SH-SY5Y cell lines.(Fig 3B).  
 
Subcellular distribution of recombinant mAng1HA and mAng1HA ALS variants in SH-
SY5Y cells 
Immunostaining for the HA tag in the stably transfected SH-SY5Y cells showed small 
punctuate granules of mAng1HA clustered adjacent to the nucleus with more diffuse 
organisation within the cytosol and along neurites. No signal was seen in the nucleus. SH-
SY5Y cells expressing K40ImAng1HA and C39WmAng1HA showed a similar distribution, 
however the dense perinuclear staining in  the two ALS variant expressing cell lines appears 
larger and more intense when compared to WT mAng1HA (Fig. 4A, arrows). This was more 
prominent in the C39W mAng1HA clone, which also appears to show reduced staining in the 
neurites. We see no effect on organelle distribution due to overexpression of any of the 
mAng1HA variants. Immunostaining showing organelle distribution in untransfected SH-
SY5Y can be found in Supp Fig 1 
We then sought to identify the intracellular route through which ANG transits during 
secretion. This was done using well characterised markers associated with distinct subcellular 
compartments: Protein disulphide isomerase (PDI) – a marker for the endoplasmic reticulum 
(ER) [29]; Trans-Golgi network protein 46 (TGN46) – a marker for the trans-Golgi network 
(TGN) [30], early endosome-associated protein (EEA1) – a marker for the early endosome 
[31], the G-protein RAB7 – a marker for the late endosome- [32] and the lysosome marker- 
lysosomal membrane protein 1 (LAMP1) [33].  
Diffuse HA staining was associated with the endoplasmic reticulum marker PDI in all 
three cell lines (Supp Fig 2). The large perinuclear accumulation partially co-localised with the 
large TGN46 compartment of the Golgi stacks for both WT-mAng1HA and the two ALS 
variants (Fig. 4A, closed arrows). In the cells expressing the mAng1 ALS variants, a proportion 
of the perinuclear accumulation did not co-localise with TGN46, and this was more prominent 
in the case of C39W mAng1HA (Fig. 4A, open arrows). No co-localisation was observed 
between mAng1HA ALS variants and the early or late endosome markers EEA1 and RAB7 
respectively (Fig. 6A and Supp Fig. 4). This strongly suggests sthat the vast majority of 
observable tagged mAng1HA is secretory rather than endocytic. Some limited co-localisation 
was seen between LAMP1 and the HA tagged mAng1 variants in neurites. (Fig. 7A, arrows). 
 
Effect of intracellular trafficking inhibitors on mAng1HA and mAng1ALS variant 
distribution 
We used small molecule inhibitors of intracellular trafficking and observed their effects 
upon the distribution of the HA tagged mAng1 and mAng1ALS variants, in order to identify 
the mechanisms and compartments through which mAng1 passes after synthesis. We used a 
broad range of inhibitors to perturb (1) ER to TGN transit (brefeldin A, [34,35]); (2) 
intracellular trafficking mediated by microtubules (nocodazole, [36]); (3) vesicular dynamics 
and lipidation of proteins (lovastatin, [37,38]); (4) pH dependent sorting (chloroquine, [39,40]), 
and (5) compartment dynamics and regulated or autophagy dependent secretion mechanism 
(wortmannin, [41,42]). 
Treatment of cells with brefeldin A resulted in the loss of the main bulk of perinuclear 
TGN46, redistributing into the ER (confirmed by wheat germ agglutinin staining [43], (Supp 
Fig. 3). The perinuclear accumulations of the mAng1HA variants were absent, presumably 
having been redistributed throughout the cell (Fig. 4B). Despite this, WTmAng1HA still 
appeared to be in small punctae within the cell body and throughout the neurites with very few 
instances of co-localisation with TGN46. A small proportion of C39WmAng1HA remained in 
a large cluster adjacent to the nucleus (Fig. 4B, arrow). 
Treatment with the microtubule disrupting agent nocodazole resulted in the loss of the 
thin well-defined neurites seen in untreated cells (Fig. 5A). Neurites, where   present after 
nocodazole treatment, taperered from a wide origin at the cell body and had little WT-
mAng1HA. In addition, the TGN46 positive trans-Golgi network  redistributed into the 
endoplasmic reticulum. Within the cell bodies large irregularly sized areas of WT and ALS-
variant mAng1HA  partially colocalised with TGN46. In SH-SY5Y cells expressing the C39W 
and K40I mAng1HA variants, the TGN46 positive compartments were seen to co-localise with 
some of the large perinuclear accumulations of mAng1HA protein in nocodazole treated cells 
(Fig. 5A, closed arrows). No further co-localisation with TGN46 is seen. The frequency and 
size of the perinuclear accumulation of mAng1HA was greater  in nocodazole treated cell lines 
when compared to  untreated mAng1HA expressing SH-SY5Y (Fig. 5A, open arrows vs. Fig. 
4A)  
The large perinuclear pool of TGN46 seen in untreated mAng1HAand mAng1HA ALS 
variant expressing SH-SY5Ycell lines appeared to be more dispersed when treated with 
lovastatin (Fig. 5B. arrows) but reamined adjacent to nucleus. HA tagged mAng1 ALS variants 
appear distributed throughout the cell in small vesicles however, co-localisation with TGN46 
was substantially reduced after exposure to lovastatin.  
Treatment with chloroquine causes larger EEA1 positive bodies to accumulate in the 
cell body adjacent to nucleus (Fig. 6B). The large perinuclear accumulations of the HA tagged 
mAng1 and mAng1ALS variants seen in untreated cells become dispersed throughout the cell 
body into smaller, more numerous accumulations.  
Upon treatment with wortmannin, LAMP1 positive compartments appeared slightly 
larger in size. This was particularly noticeable in the LAMP1+ compartments present above 
the nucleus (Fig. 7B). Co-localisation of HA tagged mAng1HA and LAMP1 was observed in 
the discrete puncta found within the cell body and neurites but not the LAMP1+ bodies above 
the nucleus after wortmannin treatment (Fig. 7B, insets). Wortmannin appear to increase the 
frequency and size of the perinuclear accumulations of mAng1HA protein similar to 
nocodazole treatment but with less severity. 
  
Discussion 
We have demonstrated that SH-SY5Y cells can secrete constitutively expressed HA-tagged 
wild type and ALS-variant mAng protein which is in the processed form and is uptake ready. 
These cell lines were then used to investigate the effects of mAng1 and its ALS variants on cell 
proliferation and differentiation We also used these overexpressing cell lines to investigate the 
intracellular secretory route taken by mAng1. We show that the neuronal cell line SH-SY5Y is 
competent to express the epitope tagged mAng1 and mAng1 ALS variant proteins from the 
transfected constructs and secrete them into the culture media  for subsequent take uptake by 
neuronal cells.  
Under normal physiological conditions, ANG is present in human serum, plasma and 
cerebrospinal fluid. ANG is also known to be constitutively secreted by multiple cancer cell 
lines, such as the adenocarcinoma cell line HT29 from which it was first identified [1]. 
Extracellular levels of ANG can be regulated either transcriptionally or by intracellular 
sequestration and release post-translationally. A well studied mechanism of  ANG upregulation 
occurs during hypoxia and involves the hypoxia inducible factor 1a (HIF-1a) [44], while HIF-
1a independent upregulation occurs in response to ER stress and unfolded protein response. 
This is mediated through inositol-requiring enzyme 1 α (IRE1 α) and protein kinase R-like 
endoplasmic reticulum kinase (PERK) in human kidney epithelium [45]. Granner et al., [46] 
have shown the secretion of ANG is increased in human adult retinal pigment epithelium cells 
in response to treatment with bevacizumab, an anti-angiogenic therapeutic. However, as only 
secreted protein was assayed the regulatory point is unknown.  
Regulated secretion of ANG (i.e. increased secretion without upregulation of 
expression) has been shown to occur in response to a variety of signals. Bone derived 
neurotrophic factor (BDNF) increases ANG secretion from vascular endothelial cells [47] and 
a wide range of signals can lead to increased ANG secretion from Mast cells. These include 
lipopolysaccharides, nerve growth factor and  peptidoglycans [48]. The role of BDNF in 
regulating the secretion of ANG from endothelial cells is unclear. ANG may have a role in 
neuroimmune modulation since Mast cells which secrete ANG have been associated with 
peripheral nerve fibres [49]. Similar tissue specific regulation of ANG secretion in response to 
environmental cues occurs in placental trophoblasts, in which vitronectin and fibronectin from  
the extracellular matrix increase both expression and secretion [50].  
The pro-proliferative role of ANG is well characterised since it is shown to induce 
proliferation in endothelial cells [51]. After uptake by the cell and translocation to the nucleus, 
ANG accumulates in nucleoli where it binds to ANG binding elements (ABEs), upregulating 
rRNA transcription and is also involved in the processing of rRNA transcripts  [52,53]. The 
increase in cell growth that  we observe in SH-SY5Y upon overexpression of WT mAng1HA  
seems more likely due to improved post-passage stress response rather than a general increase 
in proliferation rate. We do not see robust nuclear translocation or nucleolar localisation 
associated with increased proliferation during re-uptake studies and proliferation rates become 
comparable between the mutant and untransfected SH-SY5Y within 48h of passage.  
We did not observe any significant differences in apoptosis between wild type and 
ALS-variant mAng1HA expressing SH-SY5Y cell lines in the undifferentiated state. However, 
upon differentiation to a more mature phenotype [23] the ALS-variant C39W shows a 
significant increase in apoptosis while WT mAng1 results in increased neurite outgrowth.  
We have previously shown that  in the case of mutations which affect ribonucleolytic 
activity without significant structural changes, the variant ANG continues to function in 
pathways such as Pi3K signalling; ANG K40I continues to show robust microglial activation 
despite lacking RNase activity, while the structural mutant P112L is impaired  [4]. It is possible 
that h the partially unfolded C39W variant [10] may not be able to participate in non-RNase 
mediated intrinsic or extrinsic apoptotic pathways that ANG is  associated with [54], while the 
K40I variant continues to retain this function. Alternatively, the partially unfolded nature of 
the C39W variant may cause increased cell death through ER stress and UPR. This is supported 
by our observation that mAng1HA C39W is mis-localised to larger peri-Golgi aggregates in 
undifferentiated cells. UPR is increasingly being shown to be involved in the pathology of 
neurodegenerative disease [55] and has been shown to be active in ALS cases carrying SOD1 
mutations [56]. 
Overexpression of the K40I variant does not lead to significantly increased apoptosis, 
however, expression of this variant does induce nuclear export of TDP43 similar to that seen 
with overexpression of C39W ALS variant. Mis-localisation of TDP43 in the cytoplasm is 
associated with stress response, particularly ER stress [57] and this pathologic distribution is 
observed in neurodegeneration and disease associated TDP43 variants are more prone to 
mislocalisation [58,59].  
Our data suggests that ANG destined for secretion follows the conventional early 
secretory pathway from the ER to the  Golgi apparatus and finally to the TGN. Anterograde 
transport of ANG from the ER to the cis-Golgi is disrupted by BFA inhibition of COPII vesicle 
formation, leaving ANG trapped in the resulting ER-Golgi super compartment. Intracellular 
trafficking of ANG during secretion is sensitive to microtubule disruption by nocodazole, 
leaving ANG trapped in perinuclear compartments and preventing trafficking  to the neurites.  
Lovastatin has been shown to reduce secretion of molecules such as matrix 
metalloproteinase 9 secreted by macrophages [60]. As an inhibitor of HMG CoA reductase, 
lovastatin is unlikely to affect the secretion of ANG though post-translational prenylational 
(ANG/mAng1 is not prenylated) nor is it likely to affect anterograde transport through 
membrane cholesterol depletion during  short incubations used in our experiments. Therefore 
the reduction in anterograde transport of mAng1 to the TGN observed after lovastatin treatment 
may be due to prenylation dependent vesicular trafficking factors such as the Rab family 
members [61–63].  
Chloroquine has been shown to increase secretion of certain proteins. Treatment of 
normal cells (human prostate stromal cells, lung fibroblasts and epithelial cells) and in cancer 
cells (lung and prostate) resulted in increased secretion of Prostate apoptosis response-4 (Par-
4) [64]. The opposite however has also been reported, such as decreased TGF-β secretion from 
glioblastoma cell lines [65]. Par-4 secretion was upregulated through its release from 
sequestration by Uveal autoantigen with coiled coil domain and Ankyrin repeats (UACA) in 
the ER and a post-Golgi Rab8b dependent mechanism [64,66]. TGF-β secretion found to be 
impaired due to the alkalisation of the compartment in which its pre-protein is processed to a 
mature form by a furin-like protease [65,67]. Beyond cleavage of the signal peptide, no post-
translational processing of ANG has been reported to date. Therefore it is unlikely that 
inhibition of modifying enzymes due to the alkalisation of compartments will  affect secretion 
of ANG. The increased distribution of small vesicles containing mAng1 throughout the cell 
may therefore indicate increased mobilisation and trafficking of TGN vesicles to the membrane 
associated with an increased rate of secretion.  
Wortmannin acts as an inhibitor of PI3K at nanomolar concentrations [68,69] but at the 
higher concentrations used here it will also inhibit myosin light chain kinase and protein kinase 
C [70]. Wortmannin has been shown to perturb the regulated secretory pathway, for example 
it causes altered insulin secretion from pancreatic beta cells [71,72], reduced neurotensin 
secretion in small bowel endocrine cells [54] and reduced histamine secretion from the model 
mast cell line RBL-2H3 [49]. These effects are thought to occur through PI3-K mediated α-
tubulin acetylation [73,74] [56]. Wortmannin has also been shown to inhibit autophagy due to 
PI3-K dependent membrane bound vesicle trafficking [75].  
Autophagy as a key regulator of protein homeostasis is also involved in secretion. 
Autophagy-dependent secretion is a mechanism that allows cytosol-resident proteins lacking 
signal peptides such as IL-1β or FGF2, aggregate prone proteins such as α-synuclein and even 
whole organelle contents to be secreted [76]. Autophagy also mediates secretion via lysosomal 
compartments, such as secretion of cathespin K from osteoclasts [77] or mutant huntingtin [78].  
ANG contains a conventional signal peptide and as we do not observe mAng1HA in 
LAMP1 (lysosome) or RAB7 (late endosome) compartments it is unlikely either of these 
pathways are involved, however, after wortmannin treatment we find increased co-occurrence 
of mAng1HA in LAMP1 compartments. Another mechanism through which autophagy and 
secretion overlap is through maintenance of regulated secretory granule contents [79]. 
Autophagy mutant mice show impaired Paneth cell granule secretion and increased 
intracellular levels of their contents (e.g. Leptin) [80].  In senescing cells this mechanism 
condenses to a lysosome-like compartment associated with the trans-Golgi apparatus which 
selectively degrades secretory proteins in transit (e.g. IL-6 and IL-8)  leading to a reduction in 
secretion [81]. Therefore the presence of ANG in LAMP1 compartments may represent ANG 
being rerouted for degradation due to reduced transport to the plasma membrane via 
wortmannin-sensitive mechanisms, a blockade of degradation in the lysosomal compartment, 
or simple mis-sorting [82]. As ANG secretion has been shown to be regulatable at the protein 
level, sorting excess for degradation may be the mechanism through which this occurs.  
The only published pharmacological inhibitor of ANG secretion is the fungal 
metabolite terrein and its glucosides [83]. The mechanism of action of terrein is largely unclear, 
however, it has been previously characterised as an inhibitor of melanogenesis through 
ubiquitination of tyrosinase and its subsequent proteasomal degradation [84,85]. Terrein 
mediated suppression of ANG secretion slows proliferation in head and neck cancer cells and 
has been reported to halt migration in human breast cancer cells and proliferation in 
oesophageal cancer cells [86–88]. Inhibition of secretion of zebrafish Rnasel (zebrafish ANG 
like molecules) by terrein causes excess branching of spinal motor axon and impaired 
vasculogenesis  [89]. It seems plausible that terrein acts on ANG secretion in a similar manner 
to that seen in melanogenesis. The higher molecular weight species of mAng1 seen by Western 
blot may represent a pool of ubiquinated mAng1 destined for degradation in the absence of 
appropriate stimulation.  
In summary, low level autocrine signalling mediated by mAng1 expressed from 
constitutive constructs is sufficient to enhance neurite outgrowth and stress mediation in the 
case of the wild type isoform while ALS-associated mutant variants increase stress and 
apoptosis in SH-SY5Y with a mature neuronal phenotype. At these levels negligible nuclear 
localisation is seen, only cytoplasmic, and no variant had any effect of proliferation therefore 
the localisation of mAng1 determines its post-secretion effects.  
mAng1 secretion follows a conventional path. Trafficking from the ER to the TGN is 
COPII and microtubule dependent. Trafficking within the TGN is dependent on secondary 
prenylated factors and regulation of protein secretion occurs through a lysosomal dependent 
mechanism rather than through sequestration in storage granules. Manipulation of autophagy 
and degradation by lysosomal targeting may lead to further means of regulating mAng1 
secretion in addition to terrein . Control of endogenous ANG secretion may have applications 
beyond slowing cancer progression.  This could allowing suppression of toxic gain of function 
ANG variants in conjunction with therapeutics.  
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Figure Legends 
 
Figure 1 –  
 
Figure 1. Over-expressed HA-tagged Angiogenin is secreted and taken up by SH-SY5Y 
(A) Growth curves of untransfected SH-SY5Y cells (yellow) and SH-SY5Y cells 
expressing mAng1HA variants: WT purple), K40I (green) and C39W (red). SH-SY5Y cells 
mAng1HA WT cells appear to grow at a faster rate during earlier time points. No significant 
difference was found between growth rates of untransfected SH-SY5Y cells, K40I and C39W 
mAng1HA expressing SH-SY5Y cells.  Mean reference corrected absorbances from three 
independent growth curves of each cell line with four replicate samples for each 24h time point. 
SEM bars.  
(B) ANG is secreted and can be seen adhered to the surface of the coverslips in SH-SY5Y 
cell cultures. SH-SY5Y cells express low levels of endogenous ANG. Immunostaining for 
endogenous hANG (anti-hANG) in SH-SY5Y cells with or without the addition of purified 
hANG in the culture medium (+hANG) shows ANG adhesion to the coverslips. Similar HA 
tag staining is seen in mAng1HA WT, C39W or K40I SH-SY5Y cell cultures, indicating 
secretion is occurring. Scale bar 25µm  
(C) Western blot against the HA tag shows the presence of mAng1HA variant proteins in 
concentrated conditioned culture medium, secreted by transgenic SH-SY5Y cells. The 17kDa 
band represents unmodified mAng1HA variants while the 21kDa species is an uncharacterised 
post-translationally modified form.   
(D) Co-culture of untransfected SH-SY5Y cells with mAng1HA expressing SH-SY5Y cells 
on a permeable membrane. 
(E) Immunostaining against the HA-tag present in recombinant WT, C39W and K40I-
mAng1HA protein in co-cultured untransfected SH-SY5Y cells. The small punctate 
distribution is lost from the neurites and cell body. Multiple large accumulations are seen 
around the nucleus in co-culture with C39W or K40I mAng1HA. Less uptake is seen on co-
culture with WT mAng1HA SH-SY5Y cells. Scale bar 25µm. 
 
  
 Figure 2 
 
Figure 2 – Over-expression of ALS variant mAng1HA leads to cytosolic TDP43 in 
differentiated SH-SY5Y 
(A) Immunostaining for neurofilament-m expression in differentiated untransfected SH-SY5Y 
cells, WT, C39W, K40I mAng1HA expressing SH-SY5Y cells. Scale bar 75µm. 
(B) Violin plots of neurofilament positive SH-SY5Y neurite lengths measured in six randomly 
selected fields in three independent experiments. Neurites of WT-mAng1HA expressing SH-
SY5Y cells are significantly longer than those of untransfected SH-SY5Y cells or C39W and 
K40I mAng1HA expressing SH-SY5Y cells. * P<0.05.  
(C) Immunostaining for the HA-tag in differentiated cell lines expressing WT, C39W and 
K40I-mAng1HA protein. WT-mAng1HA staining appears concentrated towards the tips of 
neurites (closed arrows) while C39W and K40I appears in concentrated swellings closer to the 
cell bodies (open arrows). Neurite paths shown by dotted lines.  Immunostaining for TDP43 
shows a nuclear distribution in both PA6 and SH-SY5Y cells with no co-localisation with HA. 
Some redistribution of TDP43 into the cytoplasm can be observed in C39W and K40I 
expressing SH-SY5Y,  indicated by *.. Scale bar 25µm. 
 
  
Figure 3 
 
 
Figure 3 – ALS variant mAng1HA over-expression increases apoptosis in differentiated 
SH-SY5Y  
(A) Immunostaining for cleaved caspase 3 in undifferentiated and SH-SY5Y cells 
differentiated on PA6 with retinoic acid and dibutyryl-cAMP. Scale bar 100µm. 
(B) The percentage of cleaved caspase 3 cells in undifferentiated cultures shows no significant 
differences in the number of apoptotic cells.  
© The percentage of cleaved caspase 3 cells in differentiated cultures shows significantly more 
apoptotic SH-SY5Y cells mAng1HA C39W cells (* P<0.05).  Cells positive for cleaved 
caspase 3 were counted in six randomly selected fields in three independent experiments. Total 
cell numbers were determined by counting DAPI positive nuclei.     
  
Figure 4 
 
 
Figure 4 – ALS-mAng1HA variants accumulate adjacent to the nucleus outside of the 
trans-Golgi.  
(A) Immunostaining for TGN46 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I. Closed arrows show co-localisation. Open arrows show larger proportions of 
the C39W-mAng1HA accumulations do not overlap with TGN46 (e-h) when compared to WT 
or K40I Scale bar 25µm.  
(B) Immunostaining for TGN46 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I treated with brefeldin A. Both TGN46 and mAngHA staining appears 
dispersed throughout the cells but will very little co-localisation.  Scale bar 25µm. 
  
Figure 5 
 
Figure 5 – Microtubule disruption leads to the dispersal of mAng1HA throughout the 
cells. 
(A) Immunostaining for TGN46 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I treated with nocodazole. Closed arrows show co-localisation. Open arrows 
show redistribution of the mAng1HA into many large accumulations throughout the cell and 
do not co-localise with TGN46. Scale bar 25µm. 
(B) Immunostaining for TGN46 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I treated with lovastatin. Closed arrows show dispersed TGN46 and unchanged 
mAng1HA distribution.  Scale bar 25µm. 
  
Figure 6 
 
Figure 6 – Perinuclear accumulations of mAng1HA redistribute throughout the cell after 
chloroquine treatment.  
(A) Immunostaining for EEA1 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I. Scale bar 25µm. 
(B) Immunostaining for EEA1 and HA tag in SH-SY5Y cells expressing mAng1HA WT), 
C39W  and K40I after treatment with chloroquine. EEA1 compartments appear larger and 
closer together. The normally perinuclear mAng1HA accumulations are smaller and dispersed 
throughout the cell.  Scale bar 25µm. 
  
Figure 7 
 
Figure 7 – mAng1HA is redirected to LAMP1 positive compartments after wortmannin 
treatment 
(A) Immunostaining for LAMP1 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I. LAMP1 can be seen in neurites shown in neurite insets from boxed areas 
WT, C39W and K40I. Infrequent co-localisation with HA staining is seen. Scale bar 25µm. 
(B) Immunostaining for LAMP1 and HA tag in SH-SY5Y cells expressing mAng1HA WT, 
C39W and K40I after treatment with wortmannin. LAMP1 can be seen in neurites shown in 
neurite insets from boxed areas WT, C39W and K40I. Co-localisation with HA staining is seen 
much more frequently in the neurites in all three clones after treatment. Scale bar 25µm. 
  
  
Table 1: Antibodies used for Immunostaining 
 
Antibody Dilution Supplier Cat# 
EEA1 1:200 Cell Signal Technologies #3288 
LAMP1 1:500 Abcam Ab24170 
PDI 1:200 Cell Signal Technologies #3501 
RAB7 1:200 Cell Signal Technologies #9367 
TGN46 1:500 Abcam Ab16052 
Human Angiogenin 1:1000 A gift from Dr. Guo-Fu Hu Clone 26-2F 
HA tag (HA.11) 1:1000 Covance 16B12 
Cleaved caspase 3 1:500 Abcam Ab2302 
Neurofilament 1:5 DSHB 2H3 
Alexa Fluor 488 goat anti-mouse 1:1000 Molecular probes A-11001 
Alexa Fluor 488 goat anti-rabbit 1:1000 Molecular probes A-11034 
Alexa Fluor 594 goat anti-rabbit. 1:1000 Molecular probes A-11037 
 
  
Supplementary data for Ferguson and Subramanian 
The secretion of the angiogenic and neurotrophic factor Angiogenin is COPII and 
microtubule dependent 
 
 
 
 
Supplemental Figure 1 - Immunostaining for intracellular trafficking organelles in SH-
SY5Y cells.  
Distribution of organelle markers in untransfected SH-SY5Y cells shown by immunostaining. 
EEA1- early endosome marker,  RAB7- late endosome marker and  LAMP1- lysosome 
marker are found close to the nucleus (closed arrows) and in neurites (open arrows). The 
trans-Golgi network marker TGN46 is predominantly localised adjacent to the nucleus 
(closed arrows) but also throughout cell (open arrows). The endoplasmic reticulum marker 
PDI is found throughout the cell body. Scale bar 25µm. 
 
 
 
Supplemental Figure 2 – PDI and mAng1HA distribution in SH-SY5Y 
Immunostaining for PDI and HA tag in SH-SY5Y cells expressing mAng1HA WT (a-d), 
C39W (e-h) and K40I (i-l). Scale bar 25µm. 
  
  
Supplemental Figure 3 – WGA redistribution confirms brefeldin A efficiency in SH-
SY5Y 
Fluorescently labelled WGA lectin staining for Golgi apparatus and immunostaining for PDI. 
Untreated (a-d) and treated with brefeldin A (e-h). Treatment results in a reduction in size of 
the Golgi apparatus and redistribution into the ER when compared to untreated. Scale bar 
25µm. 
  
 
 
 
Supplemental Figure 4 –mAng1HA does not co-localise with RAB7 
Immunostaining for RAB7 and HA tag in SH-SY5Y cells expressing mAng1HA WT (a-d), 
C39W (i-l) and K40I (q-t). RAB7 can be seen in neurites shown in neurites in insets of boxed 
areas WT (e-h), C39W (m-p) and K40I (u-x). No co-localisation with HA staining is seen. 
Scale bar 25µm. 
 
 
 
